ACAM2000: the new smallpox vaccine for United States Strategic National Stockpile
- PMID: 20531961
- PMCID: PMC2880337
- DOI: 10.2147/dddt.s3687
ACAM2000: the new smallpox vaccine for United States Strategic National Stockpile
Abstract
Smallpox was eradicated more than 30 years ago, but heightened concerns over bioterrorism have brought smallpox and smallpox vaccination back to the forefront. The previously licensed smallpox vaccine in the United States, Dryvax (Wyeth Laboratories, Inc.), was highly effective, but the supply was insufficient to vaccinate the entire current US population. Additionally, Dryvax had a questionable safety profile since it consisted of a pool of vaccinia virus strains with varying degrees of virulence, and was grown on the skin of calves, an outdated technique that poses an unnecessary risk of contamination. The US government has therefore recently supported development of an improved live vaccinia virus smallpox vaccine. This initiative has resulted in the development of ACAM2000 (Acambis, Inc.), a single plaque-purified vaccinia virus derivative of Dryvax, aseptically propagated in cell culture. Preclinical and clinical trials reported in 2008 demonstrated that ACAM2000 has comparable immunogenicity to that of Dryvax, and causes a similar frequency of adverse events. Furthermore, like Dryvax, ACAM2000 vaccination has been shown by careful cardiac screening to result in an unexpectedly high rate of myocarditis and pericarditis. ACAM2000 received US Food and Drug Administration (FDA) approval in August 2007, and replaced Dryvax for all smallpox vaccinations in February 2008. Currently, over 200 million doses of ACAM2000 have been produced for the US Strategic National Stockpile. This review of ACAM2000 addresses the production, characterization, clinical trials, and adverse events associated with this new smallpox vaccine.
Keywords: efficacy; safety; smallpox; vaccine; vaccinia; variola.
Figures

Similar articles
-
Human antibody responses to the polyclonal Dryvax vaccine for smallpox prevention can be distinguished from responses to the monoclonal replacement vaccine ACAM2000.Clin Vaccine Immunol. 2014 Jun;21(6):877-85. doi: 10.1128/CVI.00035-14. Epub 2014 Apr 23. Clin Vaccine Immunol. 2014. PMID: 24759651 Free PMC article.
-
ACAM2000: a newly licensed cell culture-based live vaccinia smallpox vaccine.Expert Opin Investig Drugs. 2008 Apr;17(4):555-64. doi: 10.1517/13543784.17.4.555. Expert Opin Investig Drugs. 2008. PMID: 18363519 Free PMC article. Review.
-
The new ACAM2000 vaccine and other therapies to control orthopoxvirus outbreaks and bioterror attacks.Expert Rev Vaccines. 2009 Jul;8(7):841-50. doi: 10.1586/erv.09.55. Expert Rev Vaccines. 2009. PMID: 19538111 Review.
-
Unintentional transfer of vaccinia virus associated with smallpox vaccines: ACAM2000(®) compared with Dryvax(®).Hum Vaccin Immunother. 2013 Jul;9(7):1489-96. doi: 10.4161/hv.24319. Epub 2013 Apr 9. Hum Vaccin Immunother. 2013. PMID: 23571177 Free PMC article. Review.
-
A novel, cell culture-derived smallpox vaccine in vaccinia-naive adults.Vaccine. 2005 May 9;23(25):3301-9. doi: 10.1016/j.vaccine.2005.01.079. Vaccine. 2005. PMID: 15837236 Clinical Trial.
Cited by
-
Smallpox Vaccination-Associated Myopericarditis.Fed Pract. 2020 Sep;37(9):434-436. doi: 10.12788/fp.0043. Fed Pract. 2020. PMID: 33029069 Free PMC article.
-
Clinical Strategies and Therapeutics for Human Monkeypox Virus: A Revised Perspective on Recent Outbreaks.Viruses. 2023 Jul 12;15(7):1533. doi: 10.3390/v15071533. Viruses. 2023. PMID: 37515218 Free PMC article. Review.
-
The prospective outcome of the monkeypox outbreak in 2022 and characterization of monkeypox disease immunobiology.Front Cell Infect Microbiol. 2023 Jul 18;13:1196699. doi: 10.3389/fcimb.2023.1196699. eCollection 2023. Front Cell Infect Microbiol. 2023. PMID: 37533932 Free PMC article.
-
Two noncompeting human neutralizing antibodies targeting MPXV B6 show protective effects against orthopoxvirus infections.Nat Commun. 2024 May 31;15(1):4660. doi: 10.1038/s41467-024-48312-2. Nat Commun. 2024. PMID: 38821921 Free PMC article.
-
A Quadrivalent mRNA Immunization Elicits Potent Immune Responses against Multiple Orthopoxviral Antigens and Neutralization of Monkeypox Virus in Rodent Models.Vaccines (Basel). 2024 Apr 5;12(4):385. doi: 10.3390/vaccines12040385. Vaccines (Basel). 2024. PMID: 38675767 Free PMC article.
References
-
- Fenner F World Health Organization. Smallpox and its eradication. Geneva: World Health Organization; 1988.
-
- Schwartz B, Lebwohl M. Complications of the smallpox vaccine. Int J Dermatol. 2005;44(4):289–292. - PubMed
-
- Henderson DA. The inside story of eradicating a worldwide killer. Amherst: Prometheus Books; 2009. Smallpox: The death of a disease.
-
- Acambis I FDA C. ACAM2000™ smallpox vaccine: Vaccines and Related Biological Products Advisory Committee (VRBPAC) 2007.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical